| Abstract: |
An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dose (MTD) of idarubicin, used in the manner, was determined to be 12.5 mg/m2/dose. Twelve of 16 (75%) evaluable patients in first marrow relapse of ALL treated at a dose of 10 or 12.5 mg/m2 entered a second complete remission, compared to 41 of 69 evaluable patients (59%) treated in a comparable way with daunorubicin (30 mg/m2) (VPLD). Prolonged myelosuppression was observed in both groups, but the frequency of documented bacterial sepsis and the duration of required hospitalization were greater among patients treated with idarubicin. No additional toxicity, specifically attributable to idarubicin, was observed at these doses. Copyright © 1992 Wiley‐Liss, Inc., A Wiley Company |
| Keywords: |
adolescent; adult; child; child, preschool; major clinical study; prednisone; cancer recurrence; cancer combination chemotherapy; drug efficacy; comparative study; liver toxicity; bone marrow; bone marrow suppression; blood toxicity; antineoplastic combined chemotherapy protocols; drug administration schedule; vincristine; acute lymphoblastic leukemia; childhood cancer; hyperglycemia; hospitalization; infant; cardiotoxicity; daunorubicin; thrombocyte count; remission induction; asparaginase; sepsis; hematopoiesis; idarubicin; toxicity; intravenous drug administration; oral drug administration; intramuscular drug administration; bone marrow metastasis; maximum permissible dose; leukemia, lymphocytic, acute, l1; human; male; female; priority journal; article; support, u.s. gov't, p.h.s.; lymphoblastic leukemia; pancreas function disorder
|
